Jun 17, 2020
ASC40 (TVB-2640) Significantly Reduced Liver Fat With a 61% Responder Rate in Phase 2 NASH Trial
May 13, 2020
Ascletis' THR- beta Agonist ASC41 Receives Approval for Clinical Trials of NASH Indication
Apr 13, 2020
Ascletis Receives IND Approval for its HIV Drug ASC09F
Mar 31, 2020
Data on NASH Candidate ASC40 to be Presented at EASL ILC 2020
Mar 24, 2020
Results from First Clinical Study Using Danoprevir to Treat Naive and Experienced COVID-19 Patients
Mar 10, 2020
Progress of the Small Sample Clinical Trial of Ganovo® and Ritonavir Combination Therapy on Novel Coronavirus Pneumonia
Feb 26, 2020
Clinical Trial of Ganovo® and Ritonavir Combination Therapy on Novel Coronavirus Pneumonia
Feb 17, 2020
Ascletis' IND Filing for Its Non-alcoholic Steatohepatitis (NASH) Drug Accepted by NMPA
Jan 22, 2020
Ascletis Received Approval of Clinical Trials in HBV Patients for ASC22, a Subcutaneously Administered PD-L1 Antibody
Nov 28, 2019
Ascletis successfully obtained Pharmaceutical Trade License and GSP Certificate, formed a Complete Commercial Layout
Oct 07, 2019
Ascletis Appoints Former Novartis Global Head Dr. Handan He as Chief Scientific Officer
Sep 30, 2019
Ascletis Announces Departure of Chief Financial Officer
Aug 27, 2019
Ascletis Received IND Approval for its NASH Drug
Aug 12, 2019
Ascletis Opens Clinical Development Shanghai Center
Aug 04, 2019
Ascletis Received IND Approval and Management Outlook of 2019 and Beyond
Apr 15, 2019
Ganovo is Eligible for the Basic Medical Insurance of Zhejiang Province - Reimbursement-by-disease
Feb 28, 2019
Ascletis Appoints Former MSD Global Vice President Dr. Zhengqing Li as Chief Medical Officer and President of R&D Greater China
Jan 13, 2019
Ascletis and Alphamab Announce Strategic Collaboration and Licensing Agreement for Anti-PD-L1 to Treat Hepatitis B and Other Viral Diseases
Nov 20, 2018
Ascletis and Roche enter exclusive Pegasys partnership in China for viral Hepatitis